Merdeka Gold Resources Tbk. vs Organon Pharma Indonesia Tbk. — how do they compare? Merdeka Gold Resources Tbk. trades at Rp8,750 (market cap 126.69T, 21.27M 24h volume), while Organon Pharma Indonesia Tbk. trades at Rp29,000 (market cap 104.4B). The key difference: Merdeka Gold Resources Tbk. is far larger — about 1213.5× Organon Pharma Indonesia Tbk.'s market cap. Which is the better fit depends on your goals.
| EMAS | SCPI | |
|---|---|---|
Market Cap | 126.69T | 104.4B |
Volume | 21.27M | — |
Lot | 212.69K | — |
Turnover | 185.05B | — |
Average Price | 8,700.43 | — |
Value | 185.05B | — |
Indicative Equilibrium Price | 8,750 | — |
Indicative Equilibrium Volume | 10.1K | — |
Trailing returns across standard periods
Latest headlines on both assets
PT Merdeka Gold Resources Tbk (formerly PT Pani Bersama Jaya) (the Company), was established in Republic of Indonesia based on Deed of Establishment No. 87 dated 20 November 2015 made before Humberg Lie, S.H., S.E., M.Kn., Notary in North Jakarta. The ultimate parent entity of the Company is PT Merdeka Copper Gold Tbk (MCG). Meanwhile, MCG is jointly controlled by PT Provident Capital Indonesia and PT Saratoga Investama Sedaya Tbk, which are respectively controlled by Winato Kartono and Edwin Soeryadjaya.
Read more on EMAS →PT Merck Sharp Dohme Pharma Tbk was established within the frame work of the Foreign Capital Investment Law No. 1 year 1967 as amended by Law No. 11 year 1970 based on Notarial Deed No. 17 dated 7 March 1972 of Djojo Muljadi, S.H. The company originally incorporated as PT. Essex Indonesia, as a joint venture between Schering Corporation, a worldwide, research-based pharmaceutical enterprise headquartered in the United States, and an Indonesian businessman.
Read more on SCPI →